Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Products under Development by Stage of Development | 8 | 1 |
| Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Products under Development by Therapy Area | 9 | 1 |
| Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Products under Development by Indication | 10 | 2 |
| Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Pipeline Products Glance | 12 | 1 |
| Early Stage Products | 12 | 1 |
| Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Products under Development by Companies | 13 | 2 |
| Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Products under Development by Universities/Institutes | 15 | 2 |
| Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Therapeutics Assessment | 17 | 5 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 1 |
| Assessment by Route of Administration | 19 | 1 |
| Assessment by Molecule Type | 20 | 2 |
| Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Companies Involved in Therapeutics Development | 22 | 7 |
| Angelini Group | 22 | 1 |
| Aurigene Discovery Technologies Limited | 23 | 1 |
| Calico LLC | 24 | 1 |
| FORMA Therapeutics, Inc. | 25 | 1 |
| Genentech, Inc. | 26 | 1 |
| Karyopharm Therapeutics, Inc. | 27 | 1 |
| OncoTartis, Inc. | 28 | 1 |
| Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Drug Profiles | 29 | 12 |
| AU-4869 Drug Profile | 29 | 1 |
| Drug to Inhibit NAMPT for Inflammation and Pain Drug Profile | 30 | 1 |
| GNE-617 Drug Profile | 31 | 2 |
| KPT-9274 Drug Profile | 33 | 1 |
| OT-82 Drug Profile | 34 | 1 |
| P- BEFizumab Drug Profile | 35 | 1 |
| P7-C3A20 Drug Profile | 36 | 1 |
| Small Molecules to Activate NAMPT for Neurological Disorders Drug Profile | 37 | 1 |
| Small Molecules to Inhibit NAMPT for Cancer Drug Profile | 38 | 1 |
| Small Molecules to Inhibit NAMPT for Oncology Drug Profile | 39 | 1 |
| STF-118804 Drug Profile | 40 | 1 |
| Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Dormant Projects | 41 | 1 |
| Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Discontinued Products | 42 | 1 |
| Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Featured News &Press Releases | 43 | 4 |
| Jun 22, 2016: Karyopharm Initiates Phase 1 Clinical Trial with KPT-9274 | 43 | 1 |
| Mar 16, 2016: Karyopharm to Present Data on Oncology drug KPT-9274 at the 2016 American Association for Cancer Research Annual Meeting | 44 | 1 |
| Apr 18, 2015: Aurigene to Present its NAMPT Inhibitors Programs at AACR 2015 | 45 | 1 |
| Nov 01, 2013: Novel drug discovery method designed by Stanford scientists | 45 | 1 |
| Apr 02, 2013: Aurigene To Present Poster On NAMPT Inhibitor Program At AACR 2013 | 46 | 1 |
| Appendix | 47 | 2 |
| Methodology | 47 | 1 |
| Coverage | 47 | 1 |
| Secondary Research | 47 | 1 |
| Primary Research | 47 | 1 |
| Expert Panel Validation | 47 | 1 |
| Contact Us | 47 | 1 |
| Disclaimer | 48 | 1 |